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Abstract
Any one model system, be it culture or animal, only recapitulates one aspect of the viral life cycle 
in the human host. By providing recent examples of animal models for Epstein Barr Virus and 
Kaposi Sarcoma-associated Herpesvirus, we would argue that multiple animal models are needed 
to gain a comprehensive understanding of the pathogenesis associated with human oncogenic 
herpesviruses. Transgenic mice, homologous animal herpesviruses, and tumorgraft and humanized 
mouse models all complement each other in the study of viral pathogenesis. The use of animal 
model systems facilitates the exploration of novel antiviral and anti-cancer treatment modalities 
for diseases associated with oncogenic herpesviruses.
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Introduction
Herpesviruses are ubiquitous in the human population and establish lifelong persistence in 
the body. Their evolutionary strategy is to be disseminated through prolonged and intimate 
contact among their hosts. For this transmission strategy to have evolved, the predominant 
phenotype of the infected carrier has to subtle – otherwise no other potential host would 
come close; the most dramatic phenotype must manifest itself only after a long period of 
asymptomatic shedding, typically after the next generation of hosts has been infected. 
Indeed, herpesviruses are normally and predominantly “silently” transmitted from mother to 
child. Mother-to-child transmission in infancy is the predominant mode for acquiring 
Epstein-Barr Virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) in endemic 
healthy populations[1,2].
Cancers associated with these two human viruses manifest themselves only in a minor 
fraction of infected individuals and only in the context of co-factors that affect the latent 
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reservoirs, e.g. malaria-associated B cell activation in the case of EBV. EBV is associated 
with multiple cancers including Burkitt lymphoma, nasopharyngeal carcinoma, a subset of 
gastric cancers, a subset of Hodgkin disease, non-Hodgkin lymphoma localized to the 
central nervous system, and post-transplant lymphoproliferative disease (PTLD) in the 
context of iatrogenic immunosuppression. Furthermore, EBV is associated with other non-
neoplastic diseases including infectious mononucleosis, oral hairy leukoplakia, lupus [3] and 
X- linked immunodeficiency [4]. These different EBV disease states represent a variety of 
infected cell types, gene expression states, and levels of host immune activation. Hence, it 
would not be possible to recapitulate all these mechanistically different outcomes of 
infection in just one animal model.
KSHV, also known as human herpesvirus 8, causes Kaposi Sarcoma (KS), primary effusion 
lymphoma, a variant of multicentric Castleman's disease and an acute replication syndrome 
associated with inflammation [5]. It is instructive to enumerate the many different scenarios 
in which KS has been observed, each representing a different host/infection stage.
(a) Classic KS is predominantly a disease of older men and speculatively associated 
with diminished immune control due to aging. It can also be thought of as the 
result of an ever-expanding reservoir of latent B cells in response to 
environmental stimuli. As this latent reservoir increases, so does the likelihood 
that deleterious mutations occur in the infected B cells.
(b) Iatrogenic KS is the result of chemical immunosuppression. Interestingly, 
switching from the T cell-selective immunosuppressant cyclosporine/FK506 to 
the T and B cell immunosuppressant rapamycin/sirolimus is associated with KS 
regression.
(c) Endemic KS, prior to the emergence of human immunodeficiency virus (HIV), 
is a disease of children in a specific geographic locale in Sub-Saharan Africa, 
which also sees a geographic clustering of malaria and Burkitt lymphoma.
(d) AIDS-KS is associated with diminished immune function due to HIV infection 
and enhanced KSHV transmission in high-risk populations. To date, almost 20 
years after the introduction of anti-retroviral therapy (ART),KS remains the 
most common cancer in people living with HIV/AIDS both in Sub-Saharan 
Africa and in the US/Europe.
(e) KS now also develops in latent HIV-infected patients on long-term ART, i.e. in 
the absence of active HIV replication and despite a reasonable number of CD4 
cells (>200). These patients tend to be older men and may represent the 
intersection of incomplete immune repertoire restoration after HIV exposure, 
long-term immune activation due to microbial translocation, and diminished 
immune function due to aging.
(f) In Sub-Saharan Africa, KS is also observed in children that acquired both HIV 
and KSHV at infancy from their mother[1].
(g) Organ and bone marrow transplantation of HIV-positive patients is now routine, 
and failure rates in ART-adherent recipients are no worse than in HIV-negative 
Dittmer et al. Page 2













patients with comparable co-morbidities. This makes sense intuitively since 
transplant-associated immunosuppressants suppress replicating CD4 T cells, the 
preferred vehicle for lytic HIV replication. Some of these transplant recipients or 
the organ donors also carry KSHV and as a consequence KSmay develop.
The above disease types each represent a different genesis from the primary infection event 
to fulminant disease, each deserving and necessitating a different animal model to capture 
and recreate the salient features of tumor development.
Kaposi sarcoma-associated herpesvirus (KSHV)
There is no animal model for KSHV. In fact there is no one, perfect model for any human 
virus. By their nature and design, all models whether a tissue culture model, 3D organ 
culture, or animal model system, represent one aspect of diseasebut never the complete 
human infection cycle. A good animal model is one that faithfully represents a part of the 
viral life cycle, or a stage of carcinogenesis, for which no other experimental systems exist. 
A good animal model system is also one that is inexpensive and easy to manipulate. It fills a 
gap in our understanding of pathogenesis and allows for the testing of anti-viral or anti-
cancer agents.
KSHV does not replicate in any species except homo sapiens. Even most primates cannot be 
productively infected by KSHV. Even in infected humans, KSHV viral loads are diminutive 
in comparison to EBV and some other herpesviruses. This is perhaps due to the multitude of 
cell innate restrictions for this virus[6,7]. Models of primary KSHV infection are limited to 
humanized mouse models[8]. These serve to reveal cellular tropism (CD19 B cells, 
macrophages), tissue preference (spleen), viral latency, interactions with other viruses, host 
immune responses, and sensitivity to replication inhibitors, such as ganciclovir. Viral 
replication in these models is extremely limited and the input dose is rarely amplified. No 
serial transmission has been demonstrated in these animals to date.
KSHV can persist in non-human primates and in rare cases causes KS-like lesions[9]. 
Again, viral replication is limited and shedding is not observed. For all intents and purposes, 
non-human primates can be considered dead-end hosts for KSHV.
Non-human Rhadinoviruses
In the absence of an infection model for the human virus, homologous viruses and 
transgenic models have been explored. Each of these mimics different aspects of the disease 
or the phenotype of a subset of viral gene products. Each of these has been successful and 
must be considered significant in its own right.
KSHV is part of the rhadinovirus sub-group of gammaherpesviruses, and rhadinoviruses are 
divided into two lineages (reviewed in [10]). One lineage is represented by KSHV and a 
primate virus named retroperitoneal fibromatosisherpesvirus (RFHV), and the other lineage 
is represented by herpesvirussaimiri (HVS) and rhesus monkey rhadinovirus (RRV). RRV 
has served as a robust animal model system for KSHV. Two independent strains of RRV 
have been sequenced and their genomes are very similar to each other and KSHV. RRV 
replicates to high titers in cell culture and the virus is readily detectable in rhesus macaques. 
Dittmer et al. Page 3













A breakthrough development was the creation of RRV recombination systems, which 
allowed for viral genetics and the exploration of individual RRV genes in the context of 
animal infections, as well as for the development of RRV as a vaccine vector[11-13]. In the 
context of simian immunodeficiency virus (SIV), RRV can induce lymphomathough KS-
like skin lesions have not been observed. HerpesvirusSaimiri (HVS) was the first 
rhadinovirus isolated from primates and the HVS shares some molecular mechanism and 
host cell targets with KSHV [10,14], although this virus infects and transforms T cells in 
culture. While KSHV has the predilection to establish latency in almost all environments, 
the primate rhadinoviruses such as RRV and HVS readily enter the lytic replication phase 
and produce plaques on primary fibroblasts. Unlike KSHV, most primate rhadinoviruses 
exhibit population seropositivity rates above 80%, i.e. similar to the alpha- and beta 
herpesviruses.
The murine homolog of KSHV is murineherpesvirus 68 (MHV68). Prior to discovery of 
KSHV, MHV68 was used as a mouse model for EBV. MHV-68 replicates to high titers in 
culture and in wild-type mice (lung, spleen) it establishes latency in CD19 B cells and the 
myeloid compartment, and can be reactivated from latency. It does not form lymphoma or 
skin lesions upon natural infection of wild-type mice; however, MHV68 can immortalize 
and transform fetal liver-derived murine B cells[15]. The advantage of mouse models is the 
ability to engineer mutations in the murine genome. Thus, this model has been utilized with 
great success to study tissue tropism, latency, and the immune response to MHV68 infection 
in the context of mice lacking certain host genes[16-18]. Most recently, the outcome of co-
infections of MHV68 with other parasites has also been reported[19,20].
Genetically engineered mouse models (GEMM) for KSHV
GEMM have contributed substantially to our understanding of non-viral human cancers as 
well as polyomavirus and papillomavirus disease (papillomavirus animal models are 
reviewed in[21]). In fact, SV40 T antigen expressed from the SV40 promoter and the human 
insulin promoter was the second genetic mouse cancer model after the ras transgenic 
“oncomouse”. GEMM allow for the study of individual viral genes in a normal tissue and 
developmental context. In the case of KSHV, which establishes a very tight latency pattern 
in B cells, all latency genes are known: the KSHV cyclin homolog, vCyc, vFLIP, kaposin, 
LANA and all viral micro RNAs are regulated by a common latency promoter, which is B 
cell specific in mice. Moreover, vIL6, K1, K15 each are regulated by their own promoters 
and the viral interferon regulatory factors (vIRF-1, −2, −3, −4) are grouped in an “operon” 
fashion. GEMM exist for vIL6[22], K1, vCyc, vFLIP[23,24], LANA and the viral micro 
RNAs[25, 26]. Each of these recapitulates a particular aspect of viral biology in the intact 
and developing animal (Figure 1B). By crossing KSHV GEMM to defined mutations in the 
host genome, conserved genetic interactions have been demonstrated in vivo, e.g. 
complementation of mir-155 by the KSHV mir-K12-11 ortholog[26]. With the exception of 
vGPCR and vIL6[27], most single KSHV gene transgenic mice form tumors after long 
latency and at low penetrance. Lymphoma development in KSHV GEMM can be increased 
by modulating host tumor pathways, such as p53 or Myc[28].
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Lastly, xenograft models have been explored to understand KSHV tumorigenesis and to 
evaluate anti-cancer agents (Figure 1A). These have the advantage of containing the entire 
genetic make-up of the KSHV-associated tumor, including tumor-specific host 
polymorphisms and mutations that contribute to the human disease phenotype. Both KSHV-
infected primary effusion lymphoma (PEL) and KS tumor models have been developed 
(Figure 1A and C). These recapitulate clinical drug efficacy data, e.g. response tomTOR 
inhibitors[29-31]. Next generation, triple gene immunodeficient mice, e.g. NOD/scid/γ2ko 
(NGS), enabled the propagation of patient PEL as ascites, i.e. without intermediate culture 
[32] and with perhaps fewer culture-acquired changes. A potential drug candidate is 
typically profiled across multiple cell lines in culture. The same precaution should be taken 
for xenograft and primary graft animal models. None of the KSHV-tumor xenograft models 
generate infectious virions. Hence, theyare most often used to study agents that target 
tumors with a latent viral gene expression profile or agents that block paracrine or autocrine 
factors induced by KSHV.
Epstein Barr Virus (EBV)
EBV is a gammaherpesvirus of the lymphocryptovirus lineage. EBV infects CD19-positive 
B cells and establishes latency (type I or 0) in CD38-positive memory B cells. During type 0 
latency only the viral non-coding RNAs (EBERs and micro RNAs) are expressed; in type I 
latency the EBNA1 protein is expressed as well. Whereas the principal cell lineages of 
KSHV lytic replication are endothelial cells and B cells, EBV can replicatelyticallyin 
epithelial cells and B cells. EBV causes types of B cell lymphoma and carcinomas 
(nasopharyngeal and a subset of gastric), which are neoplasms of epithelial cells. The 
biggest biological difference between EBV and KSHV is that EBV can transform mature 
CD19-positive B cells in culture, whereas KSHV cannot. These EBV-drivenlymphoblastoid 
lines (LCL) are immortal and tumorigenic in NGS mice.
EBV does not infect mice or other rodents (although there does exist literature of EBV 
causing disease in New Zealand white rabbits). Models of primary EBV infection are thus 
limited to humanized mouse models, several of which have been described and used to 
characterize viral mutants[33,34]. In these models, particularly in T cell deficient humanized 
mouse models, EBV induces fatal lymphoma with a latency type III gene expression pattern, 
similar to PTLD. Lytic amplification and transmission through mouse saliva has not been 
reported, though this has not been exhaustively studied.
Non-human lymphocryptoviruses
Lymphocryptoviruses including EBV are found in all non-human primates. Rhesus 
lymphocrytovirus (rhLCV), which shows homology to human EBV, is used as a model 
system to study EBV[35,36]. ArhLCMV bacterial artificial chromosome (BAC) has become 
available for rhLCMV[37]. The widespread introduction of BAC technologies for human 
and animal herpesviruses in the past years has revolutionized genetic approaches to these 
viruses in culture as well as in animal models. The effect of deletions of certain rhLCV 
genes on viral replication and persistence hasbeen very informative[38]. MHV68 is also 
used as a mouse homolog of EBV (in addition to KSHV), and has been used in 
immunological studies. MHV68 mimics certain signature aspects of EBV biology, e.g. the 
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presence of small RNAs[39-41], which can be explored in the context of the authentic lytic 
infection cycle.
GEMM of EBV
Similar to KSHV, single transgene GEMM of EBV have revolutionized our understanding 
of EBV lymphomas as well as EBV-associated carcinomas. Ectopic expression of the viral 
transforming genes LMP1 and LMP2 induce drastic changes in B cell development if 
directed to the B cell lineage [3,42] and significant epithelial cell hyperplasia when driven 
by a keratin promoter. These studies have highlighted the fact that LMP1 is a homolog of 
CD40. Co-expression of LMP1 and LMP2 together, and with cellular oncogenes such as 
Myc (which is translocated in the majority of Burkittlymphoma) allowed for new insights 
into B cell reprogramming by these proteins[43-46].
Xenograft models of EBV-associated tumors have been essential to our understanding of 
EBV tumorigenesis. The most representative model of nasopharyngeal carcinoma (NPC) 
relies on serial in vivo passage of tumor explants, since the EBV episome is rapidly lost from 
NPC tumor cells upon growth in culture. The same phenotype of episome loss upon culture 
is also observed in KS-explant cell lines, but never in human tumors or the animal xenograft. 
This phenomenon underscores the idea that growth in immunodeficient mice provides a 
microenvironment and unique stromal-tumor cell interactions similar to human tumors, and 
that much of the oncogenic functions of these two large DNA tumor viruses evolved to 
engage neighboring, uninfected and untransformed cells. At this point these functions cannot 
be explored in cell culture models.
Conclusions
There is no one superior, animal model for any human virus. By their nature and by their 
design all animal models represent one aspect of the disease progress and not the complete 
lifecycle of a human tumor virus. Each of these animal models reveals a different and 
important aspect of viral infection more clearly than in the human patient. Each of these 
models offers the opportunity for experimental manipulation and hypothesis testing in 
contrast to human clinical studies, which are only correlative by nature. The ever increasing 
ease of germline manipulations in mice combined with the integration of genomic 
approaches in clinical and experimental studies make for an exciting future of investigating 
human disease through animal models.
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• Due to the fact that any particular model system only recapitulates one aspect of 
viral pathogenesis, we postulate that multiple animal models are needed to fully 
understand the biology of oncogenic herpesviruses.
• Transgenic mice, homologous animal viruses, tumorgraft and humanized mouse 
models of infection complement each other for the comprehensive study of viral 
oncogenesis.
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(A) Exudate after intraperitoneal growth of a PEL cell line (BCBL-1) in immunodeficient 
(C.B.17-SCID) mice Wright-giemsastain at 400× magnification. (B) Spleen section of 
KSHV-latency locus transgenic mice stained for the B cell marker B220 (red) and 
counterstained with hematoxylin ; MZ marginal zone (200× magnification).
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(C)KS-like lesion induced by the KSHV positive, human L1T2 (ATCC cat# VR1802) tumor 
cells under the skin of immunodeficient mice. VEGF-receptor2 (VEGF2) stain at 100× 
magnification.
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